2. Epigenetics Metabolic Enzyme/Protease Cell Cycle/DNA Damage Apoptosis Immunology/Inflammation
  3. Histone Demethylase TLK Apoptosis PD-1/PD-L1
  4. LSD1/TLK1-IN-1

LSD1/TLK1-IN-1  (Synonyms: J54; J3-54)

Cat. No.: HY-149213 Purity: 99.20%
COA
SDS
Handling Instructions Technical Support

LSD1/TLK1-IN-1 is an orally active LSD1, TLK1, TLK2, TTK inhibitor with an LSD1 IC50 of 0.247 μM. LSD1/TLK1-IN-1 suppresses phosphorylation of Nek1 at T141 and Rad9 at S328, abrogates the TLK1>Nek1>ATR>Chk1 axis, protects H3K4me1/2 from demethylation, and does not affect LSD2, MAO-A, or MAO-B. LSD1/TLK1-IN-1 induces apoptosis, bypasses cell-cycle arrest, suppresses tumor growth, downregulates PD-L1 expression, enhances T-cell killing response, inhibits gastric cancer cell proliferation. LSD1/TLK1-IN-1 can be used for the research of prostate cancer and gastric cancer.

For research use only. We do not sell to patients.

LSD1/TLK1-IN-1

LSD1/TLK1-IN-1 Chemical Structure

CAS No. : 4734-59-2

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

LSD1/TLK1-IN-1 Related Antibodies

Top Publications Citing Use of Products

View All Histone Demethylase Isoform Specific Products:

View All Isoforms
KDM1/LSD1 KDM2 KDM3 KDM4 KDM5 KDM6 KDM7

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

LSD1/TLK1-IN-1 is an orally active LSD1, TLK1, TLK2, TTK inhibitor with an LSD1 IC50 of 0.247 μM. LSD1/TLK1-IN-1 suppresses phosphorylation of Nek1 at T141 and Rad9 at S328, abrogates the TLK1>Nek1>ATR>Chk1 axis, protects H3K4me1/2 from demethylation, and does not affect LSD2, MAO-A, or MAO-B. LSD1/TLK1-IN-1 induces apoptosis, bypasses cell-cycle arrest, suppresses tumor growth, downregulates PD-L1 expression, enhances T-cell killing response, inhibits gastric cancer cell proliferation. LSD1/TLK1-IN-1 can be used for the research of prostate cancer and gastric cancer[1][2].

IC50 & Target[1]

TLK1

 

TLK2

 

In Vitro

LSD1/TLK1-IN-1 (compound J3-54) (20 μM; range; 30 minutes) potently inhibits recombinant human TLK1B kinase activity in vitro, with a Km of 31.31 μM in competitive ATP-binding assays[1].
LSD1/TLK1-IN-1 (6-20 μM; 72 h) induces weak dose-dependent proliferation inhibition in multiple prostate cancer cell lines, causes dose-dependent viability loss in LNCaP and TRAMP-C2 cells over 72 hours, and has no effect on normal RWPE1 prostate cells[1].
LSD1/TLK1-IN-1 (2-3 weeks) alone reduces colony formation in LNCaP, VCaP, and TRAMP-C2 androgen-sensitive prostate cancer cells, and causes a 4- to 5-fold greater suppression when combined with bicalutamide[1].
LSD1/TLK1-IN-1 (5-10 μM; 12-24 h) alone causes a modest S-phase reduction in LNCaP cells, and when combined with Bicalutamide (HY-14249), induces apoptosis and bypasses G1 cell cycle arrest in LNCaP, VCaP, and TRAMP-C2 cells, while suppressing TLK1B-mediated DNA damage response signaling[1].
LSD1/TLK1-IN-1 (compound 3S) potently inhibits recombinant LSD1 with an IC50 of 0.247 μM[2].
LSD1/TLK1-IN-1 (10 μM) shows high selectivity for LSD1, with less than 10% inhibitory activity against LSD2, MAO-A, and MAO-B at 10 μM[2].
LSD1/TLK1-IN-1 (0.5 μM; 6 h) directly binds to cellular LSD1 in BGC-823 gastric cancer cells when treated at 0.5 μM for 6 h, as demonstrated by enhanced LSD1 thermal stability in CETSA[2].
LSD1/TLK1-IN-1 (5-20 μM) dose-dependently suppresses PD-L1 expression via reducing PD-L1 mRNA transcription in an LSD1-dependent manner in BGC-823 and MFC gastric cancer cells when treated at 5, 10, 20 μM, with no effect on LSD1 KO cells[2].
LSD1/TLK1-IN-1 (5-20 μM) dose-dependently enhances T-cell killing response against BGC-823 gastric cancer cells via an LSD1- and PD-L1-dependent manner when treated at 5, 10, 20 μM, increasing IFNγ and TNFα secretion and reducing PD-1 binding[2].
LSD1/TLK1-IN-1 does not alter the proliferation of BGC-823 or MFC gastric cancer cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

LSD1/TLK1-IN-1 Related Antibodies

Cell Proliferation Assay[1]

Cell Line: Prostate cancer cell lines (LNCaP, VCaP, C4-2B, 22RV1, DU145, PC3, TRAMP-C2), normal prostate RWPE-1 cells
Concentration: 6-18 μM (proliferation assays); 5,13,20 μM (viability assays)
Incubation Time: 72 h (viability assays)
Result: Induced weak dose-dependent proliferation inhibition in most tested cell lines, with maximal efficacy at 18 μM.
Showed no effect on RWPE1 normal prostate cells.
Caused dose-dependent loss in cell viability over 72 hours in LNCaP and TRAMP-C2 cells, with significant reductions at 13 and 20 μM.
Inhibited VCaP cells by 60% when used alone.

Cell Cycle Analysis[1]

Cell Line: Androgen-sensitive prostate cancer cell lines (LNCaP, VCaP, TRAMP-C2)
Concentration: 5 μM (cell cycle analysis); 10 μM (Rad9 phosphorylation assay)
Incubation Time: 24 h (cell cycle analysis); 12 h (Rad9 phosphorylation assay)
Result: Caused a modest reduction in S-phase cells in LNCaP cells when used alone.
Induced a strong increase in apoptotic sub-G1 cells (33% in LNCaP, 26% in TRAMP-C2) and bypassed BIC-induced G1 cell cycle arrest when combined with bicalutamide (BIC).
Reduced phosphorylation of Nek1-T141, Rad9-S328, ATR, and Chk1 in all three cell lines.
Caused a modest increase in p-ATR in LNCaP and TRAMP-C2 cells when used alone.
Induced cleaved caspase 3, cleaved PARP, γH2AX, and p21 expression, markers of apoptosis and DNA damage, when combined with BIC.

Western Blot Analysis[2]

Cell Line: BGC-823 gastric cancer cells, LSD1 KO BGC-823 gastric cancer cells, MFC gastric cancer cells, LSD1 KO MFC gastric cancer cells
Concentration: 5-20 μM
Incubation Time: 5 days (membrane PD-L1 analysis)
Result: Dose-dependently reduced total PD-L1 protein levels, membrane PD-L1 levels, and PD-L1 mRNA levels in BGC-823 and MFC cells.
Had no effect on PD-L1 expression in LSD1 KO BGC-823 and LSD1 KO MFC cells.
Reversed PD-L1 upregulation induced by wild-type LSD1 transfection, but not by LSD1 K661A mutant transfection, in LSD1 KO BGC-823 cells.
Parmacokinetics
Species Dose Route Cmax
Mice[1] 10 mg/kg i.p. 100 ng/mL
In Vivo

LSD1/TLK1-IN-1 (compound J3-54) (5 mg/kg; i.p.; biweekly) administered intraperitoneally at 5 mg/kg biweekly significantly suppresses LNCaP xenograft tumor growth and promotes apoptosis by inhibiting the TLK1B > pNek1 DNA damage response pathway, with enhanced efficacy when combined with bicalutamide[1].
LSD1/TLK1-IN-1 (compound 3S) (10-50 mg/kg; p.o.; daily; 14 days) dose-dependently inhibits gastric cancer tumor growth in immunocompetent mice, enhances intratumoral T-cell infiltration and activity, and reduces intratumoral PD-L1 expression without significant systemic toxicity[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NOD/SCID (male)[1]
Dosage: 5 mg/kg
Administration: i.p.; biweekly
Result: Significantly suppressed tumor growth and tumor weight compared to control.
Suppressed phosphorylation of Nek1-T141 in tumor tissues.
Reduced Ki67 staining.
Increased staining for cleaved PARP, cleaved caspase 3, and γH2AX.
When combined with bicalutamide, resulted in complete suppression of tumor growth, actual tumor regression compared to starting size, and the most pronounced reductions in proliferation markers and increases in apoptosis/DNA damage markers among all groups.
Animal Model: 615 mice (male, 4−5 weeks old)[2]
Dosage: 10 mg/kg; 25 mg/kg; 50 mg/kg
Administration: p.o.; daily; 14 days
Result: Suppressed MFC tumor growth in a dose-dependent manner.
Significantly decreased tumor weights in all treatment groups compared to control.
Significantly reduced Ki67 expression in tumors.
Decreased intratumoral PD-L1 expression in a dose-dependent manner.
Significantly increased the number of intratumoral CD3+, CD4+, and CD8+ T cells.
Upregulated mRNA and protein levels of the T-cell cytokines IL2 and IFNγ in tumors.
Observed no significant differences in mouse body weight between treatment and control groups.
Detected no significant histopathological toxicity in the heart, liver, spleen, lungs, or kidneys of treated mice.
Molecular Weight

312.43

Formula

C18H20N2OS
CAS No.
Appearance

Solid

Color

Pale purple to purple

SMILES

N1(CCN2C3=C(SC4=C2C=CC=C4)C=CC=C3)CCOCC1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (320.07 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.2007 mL 16.0036 mL 32.0072 mL
5 mM 0.6401 mL 3.2007 mL 6.4014 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 2.5 mg/mL (8.00 mM); Clear solution; Need ultrasonic

    This protocol yields a clear solution of 2.5 mg/mL.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.2007 mL 16.0036 mL 32.0072 mL 80.0179 mL
5 mM 0.6401 mL 3.2007 mL 6.4014 mL 16.0036 mL
10 mM 0.3201 mL 1.6004 mL 3.2007 mL 8.0018 mL
15 mM 0.2134 mL 1.0669 mL 2.1338 mL 5.3345 mL
20 mM 0.1600 mL 0.8002 mL 1.6004 mL 4.0009 mL
25 mM 0.1280 mL 0.6401 mL 1.2803 mL 3.2007 mL
30 mM 0.1067 mL 0.5335 mL 1.0669 mL 2.6673 mL
40 mM 0.0800 mL 0.4001 mL 0.8002 mL 2.0004 mL
50 mM 0.0640 mL 0.3201 mL 0.6401 mL 1.6004 mL
60 mM 0.0533 mL 0.2667 mL 0.5335 mL 1.3336 mL
80 mM 0.0400 mL 0.2000 mL 0.4001 mL 1.0002 mL
100 mM 0.0320 mL 0.1600 mL 0.3201 mL 0.8002 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

LSD1/TLK1-IN-1 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

LSD1/TLK1-IN-14734-59-2J54 J3-54J 54J-54Histone DemethylaseTLKApoptosisPD-1/PD-L1Tousled-like kinasePD-1/Programmed death-ligand 1TLK1LSD1Nek1H3K4me1TLK2TTKRad9H3K4me2gastric cancerprostate cancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
LSD1/TLK1-IN-1
Cat. No.:
HY-149213
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (254 KB) Français - FR (254 KB) Deutsch - DE (254 KB) Norwegian - NO (254 KB) Español - ES (254 KB) Swedish - SV (254 KB) Italian - IT (254 KB) Korean - KR (254 KB) Portuguese - PT (254 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.